Changes to these pathways are pivotal in the development of severe diseases, including autoimmune conditions and cancer.
Sitryx is building a broad and differentiated pipeline by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.
Metabolic changes within cells of the immune system can drive the pathology of a disease. By intervening in cell metabolism, inflammation and tissue damage can be reversed and resolved, leading to better patient outcomes.
Metabolic changes can contribute to pathology →
← Metabolic intervention can reverse changes
Most modern anti-inflammatory and oncology drugs intervene at a particular point causing immunosuppression with limited results. Changing the state of different combinations of immune cells can have a much more wide-ranging impact to potentially resolve inflammation.
Blocking cytokines at one particular point results in targeted immunosuppression and resolution of disease in a limited subset of patients.
Targeted metabolic intervention can shift cells to a non-inflammatory pro-resolution state, offering the potential for a broader population of patients to achieve disease remission.
Different cells of the immune system are implicated in different diseases and hence different groups of cells of the immune system can be targeted by intervening at particular points of metabolism.
By targeting a range of points of metabolic control, Sitryx can build a portfolio across a range of diseases.
T Reg cell
Tumour assoc. T Reg
Tumour assoc. macrophage
|Profile 1Psoriasis, MS, GVHD, SLE, refractory RA, fibrosis|
|Profile 2Psoriasis, MS, GVHD, SLE|
|Profile 3IL-17 and antibody-mediated diseases|
|Profile 4Antibody-mediated diseases, MS, GVHD|
|Profile 5IL-17 mediated-diseases|
Intervening in cell metabolism, to reverse and resolve inflammation and tissue damage, leading to better outcomes.
Offering the potential for a broader population of patients to achieve remission in a range of severe diseases in immunology and oncology.